Diuretic Therapy in Heart Failure Management

Diuretic therapy remains a cornerstone in the management of heart failure, targeting intravascular and interstitial volume overload to alleviate symptoms, improve exercise tolerance and reduce hospital admissions. Loop diuretics achieve potent natriuresis by inhibiting the Na+-K+-2Cl– cotransporter in the thick ascending limb of the loop of Henle, while thiazides, mineralocorticoid antagonists and carbonic anhydrase inhibitors provide adjunctive mechanisms to address residual fluid retention and neurohormonal activation. Despite clear symptomatic benefits, variability in patient response, risks of electrolyte disturbances, renal impairment and diuretic resistance pose ongoing clinical challenges. Optimising dose regimens, timing of administration and combination strategies has become essential to balance decongestion with preservation of renal function and avoidance of adverse events. Emerging personalised approaches seek to integrate biomarkers, haemodynamic monitoring and circadian biology to refine treatment and improve long-term outcomes.

Research from Nature Portfolio

Recent studies have shown that a natriuresis-guided algorithm for intravenous loop diuretics in acute heart failure can significantly increase 24-hour sodium excretion compared with standard care, demonstrating the feasibility of a biomarker-driven dosing strategy. While this approach improved early decongestion metrics, it did not translate into reductions in mortality or rehospitalisation at six months, underscoring the need for further refinement of personalised protocols. Mechanistic insights into renal handling of sodium and the interplay between tubular function and systemic haemodynamics are informing the next generation of diuretic dosing algorithms aimed at maximising decongestive efficacy while minimising renal and electrolyte complications.

Diuretic Therapy in Heart Failure Management publication trend

The graph below shows the total number of articles in diuretic therapy in heart failure management across all publications each year (not limited to Nature Index journals).

Technical terms

Loop diuretics: Agents that inhibit the Na+-K+-2Cl– cotransporter in the thick ascending limb of the loop of Henle to promote water and sodium excretion.

Natriuresis: Excretion of sodium in the urine, often used as a biomarker of diuretic efficacy.

Diuretic resistance: A reduced response to diuretic therapy resulting in inadequate decongestion despite escalating doses.

Bioavailability: Proportion of an administered drug that reaches the systemic circulation in an active form.

Chronotherapy: Timing of medication administration to align with biological rhythms to optimise efficacy and minimise side effects.

References

1. Natriuresis-guided diuretic therapy in acute heart failure: a pragmatic randomized trial. Nature Medicine (2023).
2. A novel, small-volume subcutaneous furosemide formulation delivered by an abdominal patch infusor device in patients with heart failure: results of two phase I studies. European Heart Journal - Cardiovascular Pharmacotherapy (2023).
3. A combined clinical and biomarker approach to predict diuretic response in acute heart failure. Clinical Research in Cardiology (2015).
4. Improving Diuretic Response in Heart Failure by Implementing a Patient-Tailored Variability and Chronotherapy-Guided Algorithm. Frontiers in Cardiovascular Medicine (2021).